Magenta and beam join to evaluate mgta-117 as conditioning regimen for base editing therapies

Magenta therapeutics and beam therapeutics announce collaboration to evaluate targeted antibody-drug conjugate (adc) mgta-117 as conditioning regimen for base editing therapies.magenta therapeutics - co, beam therapeutics announced non-exclusive collaboration agreement to evaluate potential utility of mgta-117.
DNTH Ratings Summary
DNTH Quant Ranking